

1 **Original Investigation**

2 **Title** Re-emergence of respiratory syncytial virus following the COVID-19 pandemic  
3 in the United States: a modeling study

4

5 Zhe Zheng, MPhil, MBBS<sup>1\*</sup>; Virginia E. Pitzer, ScD<sup>1</sup>; Eugene D. Shapiro, MD<sup>2</sup>;

6 Louis J. Bont, MD, PhD<sup>3,4</sup>; Daniel M. Weinberger, PhD<sup>1</sup>

7

8 <sup>1</sup>Department of Epidemiology of Microbial Diseases and the Public Health Modeling  
9 Unit, Yale School of Public Health, New Haven, CT, USA.

10 <sup>2</sup> Department of Pediatrics, Yale University School of Medicine, New Haven, CT,  
11 USA.

12 <sup>3</sup> Department of Pediatrics and Department of Immunology, University Medical  
13 Center Utrecht, Utrecht University, University Medical Center Utrecht, Utrecht, the  
14 Netherlands.

15 <sup>4</sup> ReSViNET Foundation , Zeist, The Netherlands.

16

17 \*Corresponding author:

18 Zhe Zheng,

19 Department of Epidemiology of Microbial Diseases,

20 Yale University,

21 60 College Street, New Haven, Connecticut, USA

22 [zhe.zheng@yale.edu](mailto:zhe.zheng@yale.edu),

23 Tel: (+1)203-298-2435

24

25 Word count: 3000 [word limit: 3000]

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract** Word count: 340 [word limit: 350]

27 **Importance:**

28 Respiratory syncytial virus (RSV) is a leading cause of hospitalizations in young  
29 children. RSV largely disappeared in 2020 due to precautions taken because of the  
30 COVID-19 pandemic. Projecting the timing and intensity of the re-emergence of RSV  
31 and the age groups affected is crucial for planning for the administration of  
32 prophylactic antibodies and anticipating hospital capacity.

33 **Objective:**

34 To project the potential timing and intensity of re-emergent RSV epidemics in  
35 different age groups.

36 **Design, Setting, Participants:**

37 Mathematical models were used to reproduce the annual RSV epidemics before the  
38 COVID-19 pandemic in New York and California. These models were modified to  
39 project the trajectory of RSV epidemics in 2020-2025 under different scenarios with  
40 varying stringency of mitigation measures for SARS-CoV-2: 1) constant low RSV  
41 transmission rate from March 2020 to March 2021; 2) an immediate decrease in RSV  
42 transmission in March 2020 followed by a gradual increase in transmission until April  
43 2021; 3) a decrease in non-household contacts from April to July 2020. Simulations  
44 also evaluated factors likely to impact the re-emergence of RSV epidemics, including  
45 introduction of virus from out-of-state sources and decreased transplacentally-  
46 acquired immunity in infants.

47 **Main Outcomes and Measures:**

48 The primary outcome of this study was defined as the predicted number of RSV  
49 hospitalizations each month in the entire population. Secondary outcomes included

50 the age distribution of hospitalizations among children <5 years of age, incidence of  
51 any RSV infection, and incidence of RSV lower respiratory tract infection (LRI).

52 **Results:**

53 In the 2021-2022 RSV season, we expect that the lifting of mitigation measures and  
54 build-up of susceptibility will lead to a larger-than-normal RSV outbreak. We predict  
55 an earlier-than-usual onset in the upcoming RSV season if there is substantial external  
56 introduction of RSV. Among children 1-4 years of age, the incidence of RSV  
57 infections could be twice that of a typical RSV season, with infants <6 months of age  
58 having the greatest seasonal increase in the incidence of both severe RSV LRIs and  
59 hospitalizations.

60 **Conclusions and Relevance:**

61 Pediatric departments, including pediatric intensive care units, should be alert to large  
62 RSV outbreaks. Enhanced surveillance is required for both prophylaxis administration  
63 and hospital capacity management.

## 64 **Introduction**

65           Respiratory syncytial virus (RSV) infection is a leading cause of acute  
66 respiratory hospitalizations in infants, young children, and the elderly.<sup>1-3</sup> Individuals  
67 develop only partial immunity following RSV infections, and this incomplete  
68 immunity permits reinfections throughout life.<sup>4</sup> Although most infants are born with  
69 protective immunity against RSV infections due to antibodies from the mother that  
70 are acquired transplacentally, this protection wanes quickly with time.<sup>5-7</sup>

71           RSV epidemics occur with notable spatiotemporal patterns in the United  
72 States, with consistent seasonal timing and duration.<sup>8,9</sup> However, the incidence of  
73 RSV in many regions in the United States has declined since the introduction of  
74 mitigation measures for COVID-19 pandemic in March 2020.<sup>10</sup> The low positivity  
75 rate continued throughout 2020 without an obvious increase in late fall and winter  
76 when seasonal RSV epidemics typically occur. Many other countries reported  
77 similarly low frequencies of RSV detection in the 2020 season.<sup>11-13</sup>

78           As mitigation measures have been gradually lifted, different patterns of RSV  
79 epidemics emerged in different regions in early 2021.<sup>10-13</sup> Later-than-usual RSV  
80 activity was reported in France, Spain and in some U.S. states.<sup>10,12,14</sup> Large out-of-  
81 season surges of RSV infections were reported in both Australia and South Africa.<sup>15,16</sup>  
82 Nonetheless, even with many restrictions lifted, RSV activity remains low in many  
83 other countries.<sup>17,18</sup> What causes these differences remains unclear.

84           The potential impacts of mitigation measures on the number, timing, and age  
85 of RSV hospitalizations are crucial for planning for the administration of RSV  
86 prophylaxis and for hospital utilization, since regular annual RSV epidemics often  
87 fully use hospital capacity in pediatric departments. However, many factors may  
88 affect when and to what extent RSV epidemics resume. For example, introduction of

89 RSV from other regions may accelerate the process, and low immunity in the  
90 population due to a low incidence of reinfections may produce a large population of  
91 susceptible individuals sufficient to trigger an outbreak.

92 Our study aims to simulate a range of potential scenarios and to inform data  
93 collection for better epidemic projections of RSV activity in the U.S. In this study, we  
94 used historical RSV inpatient data, combined with validated transmission dynamic  
95 models, to evaluate the potential patterns of re-emergence of RSV epidemics with  
96 different stringencies of mitigation measures. We also examined how the age  
97 distribution of RSV infections and hospitalizations might be expected to change in the  
98 coming years following these different scenarios.

## 99 **Methods**

### 100 **Data**

101 RSV-specific hospitalization data for New York (2005-2014) and California  
102 (2003-2011) were obtained from State Inpatient Databases of the Healthcare Cost and  
103 Utilization Project maintained by the Agency for Healthcare Research and Quality.<sup>19</sup>  
104 These comprehensive databases contain all hospital discharge records from  
105 community hospitals in participating states. Datasets include the month of  
106 hospitalization and the age of the patient. A hospitalization was defined as due to  
107 RSV if any of the discharge diagnostic codes included 079.6 (RSV), 466.11  
108 (bronchiolitis due to RSV), or 480.1 (pneumonia due to RSV), based on the  
109 International Classification of Disease Ninth Revision [ICD-9].<sup>20</sup> Information about  
110 population size in each age group was obtained from the US Census Bureau's  
111 American Community Survey.<sup>21</sup> Birth rate by year and state was obtained from CDC  
112 vital statistics.<sup>22</sup> RSV surveillance data for California (2009-2018) were obtained  
113 from the Immunization Branch, California Department of Public Health and were

114 used to validate model prediction.<sup>23</sup> We also performed sensitivity analyses using  
115 parameters fitted to a similar inpatient dataset from Colorado to illustrate potential  
116 impacts of mitigation measures on biennial RSV epidemics.<sup>24</sup>

117

## 118 **Simulations**

119 To predict RSV transmission dynamics, we extended a previously published  
120 RSV transmission model (see Supplement for details, Figures S1-S3).<sup>24</sup> We generated  
121 forward simulations using varying input parameters (see Supplement for details),  
122 assuming the same immigration/emigration, death and birth rate as 2019. We used  
123 fixed control periods in our main analysis. We also considered various durations of  
124 the control periods and the impacts of mitigation measures on RSV transmission  
125 dynamics in states with different epidemic timing, including biennial epidemics, as  
126 sensitivity analyses.

127 We simulated the monthly number of RSV hospitalizations from 2021 to  
128 2025. With many unknowns, our aim was to explore a wide range of possible  
129 scenarios (see Box 1) rather than making precise predictions.

### 130 *Decrease in transmission*

131 We evaluated a range of reductions in the RSV transmission rate, from 10% to  
132 25%, based on the results of a previous study analyzing the impact of mitigation  
133 measures on seasonal respiratory viruses.<sup>25</sup> We evaluated two kinds of decrease in  
134 transmission beginning in March 2020 and lasting until April 2021: 1) a constant  
135 decrease, and 2) a large decrease followed by a linear increase in transmission. The  
136 rationale for the second type of decrease comes from reports that mitigation measures  
137 were strictest at the beginning of the COVID-19 pandemic and were gradually relaxed  
138 with time.<sup>26-28</sup>

139 *Changes in contact patterns*

140 We also explored the impacts of heterogeneous changes in contact patterns on  
141 RSV epidemics. Specifically, we examined the effects of a three-month stay-at-home  
142 order from April 1 to July 1, 2020.<sup>26,28</sup> We calculated the percentage of household  
143 contacts in detailed age groups and multiplied by the age-specific contact rates of  
144 respiratory-spread infectious agents in the corresponding age groups.<sup>29-31</sup> We assumed  
145 an 82%<sup>32</sup> decrease in non-household contacts and a 10%<sup>33</sup> increase in household  
146 contacts.

147 *Impact of virus introduction from external sources*

148 Stay-at-home orders and travel restrictions may also have an effect on the  
149 introduction of RSV into a population. Travel restrictions between countries and  
150 states may limit the introduction of external RSV infections, while constant virus  
151 seeding from other regions may accelerate the re-emergence of RSV epidemics. There  
152 is little data on the rate of infections of RSV that are imported from other regions.  
153 Therefore, we explored a range of 1 to 10 imported infections per 100,000 population  
154 per month. We assumed these external infections are mild and do not lead to LRI or  
155 hospitalization. In the main analysis, we assumed the number of external infections  
156 decreased to 0 in April 2020 and gradually increased back to 40% of the original level  
157 in February 2021 based on changes in weekly total air travel.<sup>34</sup> We also explored  
158 various other scenarios (see Supplement).<sup>35</sup>

159 *Impact of decreased duration of transplacentally-acquired immunity in infants*

160 Reduction in transmission results in low virus activity in the community,  
161 which may cause fewer exposure opportunities for the general population. Because  
162 virus exposure can boost immunity levels,<sup>36</sup> pregnant women may have lower  
163 concentrations of antibodies because of lack of boosting from a lower rate of

164 exposure. Correspondingly, the level and duration of the immunity in infants acquired  
165 from their mothers may also decrease. Since few previous studies quantified how  
166 virus exposure in pregnant women may affect the duration of transplacentally-  
167 acquired immunity in infants, we probed the effect of a lack of boosting by proposing  
168 a range of possible decreases in the duration of transplacentally-acquired immunity on  
169 top of the linear change in RSV transmission. The period of shortened  
170 transplacentally-acquired immunity is therefore dependent on the RSV epidemics,  
171 from November 2020 to October 2021 based on observations and the results of  
172 simulations.

### 173 **Outcome Measures**

174 The primary clinical outcome of interest is the predicted monthly number of  
175 RSV hospitalizations. Secondary outcomes of interest included the age distribution of  
176 hospitalizations among children under 5 years of age, incidence of any RSV infection,  
177 and incidence of RSV lower respiratory infection. Percentage changes in incidence  
178 were calculated by comparing the differences between the predicted incidence in the  
179 2021-2022 RSV season with and without changes to the transmission rate related to  
180 mitigation measures (see Supplements for details).

### 181 **Results**

#### 182 *Expected timing of the re-emergence of RSV under different scenarios*

183 Under Scenario 1, we assumed that transmission decreased homogeneously by  
184 20% from March 2020 to March 2021 without any external source of infections. In  
185 this case, the model predicted an absence of RSV epidemic in 2021 and an out-of-  
186 season outbreak starting in the summer of 2022. Models with constant low  
187 transmission took more than a year to resume annual epidemics (Figure 1A).



188           Compared with the constant low transmission rate scenario, a sudden decrease  
189   in RSV transmission in March 2020 followed by a linear increase over a 13-month-  
190   period (Scenario 2) allowed for sufficient infections to trigger a large outbreak in the  
191   winter of 2021-2022. With this scenario, we would expect to see epidemics return to  
192   annual cycles in the winter of 2022-2023 (Figure 1A). Models with smaller decreases  
193   in transmission generally generated earlier re-emergence of RSV epidemics (Figure  
194   S4).

195           In the third scenario, a three-month stay-at-home order beginning in April  
196   2020 substantially reduced the number of non-household contacts and resulted in a  
197   delayed, small uptick in RSV infections. With these conditions, infections re-emerge  
198   around February-March 2021, rather than the expected November 2020. The RSV  
199   epidemic in the 2021-22 season is expected to have an earlier onset and peak timing  
200   than the usual RSV season under this scenario (Figure 1A).

201           The scenarios described above assume no external introduction of RSV  
202   infections. In contrast, if Scenario 2 (20% linear change in transmission) was  
203   modified to allow for the external introduction of infections during the control period  
204   (Scenario 4), a small increase in RSV hospitalizations would have been expected in  
205   the winter and spring of 2020-2021. This increase is expected to be followed by a  
206   small spike corresponding to a return to normal virus importation due to lifted  
207   restrictions on inter-state travel. Based on this scenario, we expect an earlier onset,  
208   higher peak number and more patients per season in the 2021-2022 than a typical  
209   RSV season (Figure 1B).

210           Based on our simulation (Scenario 5), shorter transplacentally-acquired  
211   immunity in infants did not substantially change the timing or the amplitude of RSV  
212   epidemics on top of the changes resulting from reduced transmission (Figure S5).

213 *Shifts in the age distribution of infection during the re-emergence of RSV*

214 As reported, mitigation measures were gradually relaxed in most of the  
215 states.<sup>26-28</sup> Therefore, we chose Scenario 2 to illustrate changes in the age distribution  
216 of infection during the re-emergence of RSV. The following findings are consistent  
217 across scenarios although the exact numbers are different. Under Scenario 2, the  
218 average age of hospitalization among children under 5 years is expected to be higher  
219 in the 2021-2022 RSV season compared with preceding years. The average age of  
220 hospitalization is predicted to gradually return back to the pre-pandemic level in 2023  
221 (Figure 2). Young children are expected to have higher incidence of hospitalizations  
222 this upcoming epidemic year (July 2021 to June 2022).

223 Across all age groups, the model predicts an 87% increase in RSV LRIs and  
224 an 83% increase in RSV hospitalizations during the 2021-2022 epidemic year under  
225 Scenario 2 compared with a typical RSV season. Looking into the details of the age  
226 distribution for different clinical outcomes, children aged 1 to 4 years are expected to  
227 have the greatest percentage increase in the incidence of RSV infection, lower  
228 respiratory infection (LRI) and hospitalization compared with a typical pre-pandemic  
229 RSV season (Figure 3). However, infants age 3 to 5 months old are expected to have  
230 the largest incidence of LRI, and infants under 3 months are expected to have the  
231 largest incidence of RSV hospitalization.

232 **Discussion**

233 Seasonal RSV epidemics have been interrupted by COVID-19 mitigation  
234 measures during 2020-2021. Understanding the potential timing, intensity and age  
235 distribution of re-emergent RSV epidemics is crucial for clinical and public health  
236 decision-making. Our results suggest that stricter mitigation measures will lead to  
237 later and larger epidemic outbreaks and a shift in the age distribution due to an

238 accumulation of susceptibility within the population. However, the importation of  
239 infections into a population may accelerate the re-emergence process and cause an  
240 earlier-than-usual outbreak in the upcoming RSV season.

241           Variation in the patterns of re-emergent RSV epidemics across regions and  
242 countries could potentially be explained with our simulated results. (1) In Australia,  
243 an island country, closing the borders and implementing a mandatory quarantine were  
244 probably sufficient to eliminate imported infections. Australia also implemented a  
245 one-month stay-at-home order in the beginning of the COVID-19 pandemic and  
246 gradually relaxed all other restrictions within three months. These short-term  
247 mitigation measures may have temporarily suppressed local RSV transmission, and  
248 the accumulation of susceptibility since the end of the previous RSV season in  
249 October 2019 may have triggered the large out-of-season outbreak. Our simulated  
250 average age of hospitalizations is similar to the reported median patient age in  
251 Australia both before the pandemic and during the re-emergent RSV epidemic.<sup>37</sup> (2)  
252 In New York, which has many and frequent connections to the other parts of the U.S.  
253 and the world, the risk of virus importation likely existed during the COVID-19 travel  
254 restriction period. The risk of virus importation depends both on the volume of travel  
255 and the level of external RSV activity. Therefore, the increase in virus importation  
256 during the control period may not be linear as travel volume increased. Before  
257 November 2020, most places in the world reported no RSV epidemics. Virus  
258 importation from other areas was therefore highly unlikely. This may be the reason  
259 that we observed a later and steeper increase in RSV epidemics during the spring of  
260 2021 (see Figure S6). (3) In Argentina and Canada, governments implemented very  
261 strict mitigation measures at the start of COVID-19 pandemic.<sup>38,39</sup> Some restrictions  
262 have been extended and remained in place as of April 2021 to protect against new

263 variants.<sup>40,41</sup> It is worth noting that these two countries represent both the northern and  
264 southern hemisphere and have opposite RSV seasons.<sup>42</sup> Nonetheless, both countries  
265 reported low RSV activity as of April 2021.

266 In all of our scenarios, the upcoming RSV season is expected to have a higher-  
267 than-normal intensity. Our analysis suggests that infants <6 months of age are  
268 expected to have about 1.5 times increased risk of LRI and hospitalization as a result  
269 of RSV infections during the upcoming RSV season. At the same time, RSV  
270 infections in children aged 1 to 4 years are expected to double regardless of severity  
271 compared with a typical RSV season. This is alarming because pediatric facilities and  
272 intensive care units may be overloaded with patients in the upcoming RSV season.<sup>43,44</sup>  
273 Even worse, the timing of re-emergent RSV epidemics varied among scenarios,  
274 making it difficult to predict the timing. Aberrations in timing may decrease the  
275 impact of palivizumab, since the administration of antibody prophylaxis for high-risk  
276 infants needs to be timed to coincide with the epidemic.<sup>45</sup> Thus, enhanced, year-round  
277 surveillance for RSV infections is needed to inform the use of palivizumab over the  
278 2021-2022 season. It is important for pediatric facilities and intensive health care  
279 units to be aware and prepared for these scenarios, especially since future RSV  
280 epidemics may occur at an unusual time.

281 Our study tested additional assumptions made by a previous study of the  
282 impact of mitigation measures on RSV dynamics by exploring a variety of scenarios,  
283 as well as considering the age distribution of cases.<sup>25</sup> Our overall projections for  
284 upcoming RSV epidemics are similar: large outbreaks are very likely once mitigation  
285 measures are relaxed.

286 Our research suggests that virus introduction affects the timing and intensity  
287 of re-emergent RSV epidemics. Research from the late 1990s in the U.S. suggested

288 that external sources of RSV infections may exist but are uncommon,<sup>46,47</sup> in contrast  
289 to a recent finding from Kenya suggesting that RSV was reintroduced into  
290 communities every year from other parts of the country.<sup>48</sup> With increased global  
291 connectivity, the mixing patterns of RSV transmission between and within  
292 communities in the U.S. may have changed. High-density sampling and sequencing of  
293 RSV across a region will be critical to understand the current level of importation of  
294 RSV infections.

295 For the re-emergent epidemics (2021-2022), our model (under Scenario 2  
296 assumption) suggests an older average age of hospitalizations. This makes intuitive  
297 sense, since many children born in 2020 were spared from RSV infection due to the  
298 low virus activity; these children will be older when they get infected for the first time  
299 during the re-emergent epidemics. Consequently, the American Academy of  
300 Pediatrics should consider modifying prophylaxis guidelines to include high-risk  
301 infants <2 years of age for the 2021-2022 season. The average age of hospitalization  
302 will gradually decrease in the following RSV seasons because of the depletion of  
303 older susceptible individuals during the first re-emergent outbreak and the constant  
304 replenishment of susceptible infants through new births and waning transplacentally-  
305 acquired immunity.<sup>49</sup>

306 There are several caveats to our results. First, we did not have explicit data on  
307 the level of virus introduction or the effects of lack of boosting on the duration of  
308 protection provided to infants by transplacentally-acquired antibodies to RSV.  
309 Although we explored a range of values, it is possible that the real values are outside  
310 of the range in our models. Our model predictions are most sensitive to the level of  
311 RSV introduction. Additional data on these factors will be helpful for future modeling  
312 of RSV transmission dynamics. Research on the relationship between virus exposure

313 and the duration of transplacentally-acquired immunity in infants may also help to  
314 explain discrepancies in the efficacy of maternal vaccines across different  
315 transmission settings.<sup>50</sup> Second, we used historical inpatient data to fit our  
316 transmission models. However, the intensity and seasonality of RSV epidemics may  
317 have changed over the past few years. To address this possibility, we explored a  
318 variety of intensity levels and both annual and biennial cycles with data from different  
319 states in our sensitivity analysis (see Figure S7-S16). Also, ongoing RSV surveillance  
320 data from California,<sup>51</sup> Florida,<sup>52</sup> Minnesota,<sup>53</sup> Oregon,<sup>54</sup> and Texas<sup>55</sup> suggests that  
321 RSV activity has been very consistent over recent years. Finally, there are other  
322 possible factors influencing re-emergent RSV epidemics, such as the impact of  
323 introduction of RSV vaccines and monoclonal antibody.<sup>56</sup> As the extended half-life  
324 antibody against RSV, Nirsevimab, has been proved to be efficacious in phase III  
325 clinical trials,<sup>57,58</sup> research on its impact may be important to elucidate future  
326 epidemics of RSV infections.

327         In conclusion, re-emergent RSV epidemics in 2021-2022 are expected to be  
328 more intense and to affect patients in a broader age range than in typical RSV seasons.  
329 The timing of re-emergent RSV epidemics may be different from the usual RSV  
330 season, depending on the duration of mitigation measures and the extent of virus  
331 introduction from other regions. Clinicians should be alert to the possibility of out-of-  
332 season RSV outbreaks.

333

334 **Acknowledgments**

335 *Competing interest declaration:* VEP has received reimbursement from Merck and  
336 Pfizer for travel expenses to Scientific Input Engagements on respiratory syncytial  
337 virus. DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for  
338 work unrelated to this manuscript and is Principal Investigator on research grants  
339 from Pfizer and Merck on work unrelated to this manuscript. L.J.B. reports grants  
340 from AbbVie, MedImmune, Janssen, Pfizer, MeMed, and the Bill & Melinda Gates  
341 Foundation. Funders had no role in design, interpretation and reporting of this study.  
342 All other authors report no relevant conflicts.

343 *Funding Statement*

344 DMW and VEP acknowledge support from grants R01AI137093 from the National  
345 Institute of Allergy and Infectious Diseases/National Institutes of Health. EDS was  
346 supported, in part, by grants number UL1TR000142 and KL2-TR001862 from the  
347 National Center for Advancing Translational Science (NCATS) at the National  
348 Institutes of Health and NIH Roadmap for Medical Research. Its contents are solely  
349 the responsibility of the authors and do not necessarily represent the official views of  
350 NIH.

351 *Other declarations:* I confirm all relevant ethical guidelines have been followed, and  
352 any necessary IRB and/or ethics committee approvals have been obtained.

353

354 **References**

- 355 1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial  
356 virus infection in young children. *The New England journal of medicine*.  
357 2009;360(6):588-598.
- 358 2. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national  
359 disease burden estimates of acute lower respiratory infections due to  
360 respiratory syncytial virus in young children in 2015: a systematic review and  
361 modelling study. *Lancet*. 2017;390(10098):946-958.
- 362 3. Tin Tin Htar M, Yerramalla MS, Moisi JC, Swerdlow DL. The burden of  
363 respiratory syncytial virus in adults: a systematic review and meta-analysis.  
364 *Epidemiology and infection*. 2020;148:e48.
- 365 4. Russell CD, Unger SA, Walton M, Schwarze J. The Human Immune  
366 Response to Respiratory Syncytial Virus Infection. *Clin Microbiol Rev*.  
367 2017;30(2):481-502.
- 368 5. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in  
369 protection of American Indian infants against respiratory syncytial virus  
370 disease. *The Pediatric infectious disease journal*. 2008;27(3):207-212.
- 371 6. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibody  
372 and respiratory syncytial virus infection in infancy. *Journal of medical*  
373 *virology*. 1981;7(4):263-271.
- 374 7. Chu HY, Steinhoff MC, Magaret A, et al. Respiratory syncytial virus  
375 transplacental antibody transfer and kinetics in mother-infant pairs in  
376 Bangladesh. *The Journal of infectious diseases*. 2014;210(10):1582-1589.
- 377 8. Boron ML, Edelman L, Groothuis JR, Malinoski FJ. A novel active  
378 respiratory syncytial virus surveillance system in the United States: variability



- 379 in the local and regional incidence of infection. *The Pediatric infectious*  
380 *disease journal*. 2008;27(12):1095-1098.
- 381 9. Respiratory Syncytial Virus Infection (RSV): Trends and Surveillance.  
382 Centers for Disease Control and Prevention. December 18, 2020;  
383 <https://www.cdc.gov/rsv/research/us-surveillance.html>. Accessed May 30,  
384 2021.
- 385 10. RSV National Trends. Centers for Disease Control and Prevention. November  
386 25, 2020; <https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html>.  
387 Accessed January 30, 2021.
- 388 11. Yeoh DK, Foley DA, Minney-Smith CA, et al. The impact of COVID-19  
389 public health measures on detections of influenza and respiratory syncytial  
390 virus in children during the 2020 Australian winter. *Clinical infectious*  
391 *diseases : an official publication of the Infectious Diseases Society of America*.  
392 2020.
- 393 12. Casalegno J-s, Javouhey E, Ploin D, et al. Delayed Start of the Respiratory  
394 Syncytial Virus Epidemic at the End of the 20/21 Northern Hemisphere  
395 Winter Season, Lyon, France. *medRxiv*. 2021:2021.2003.2012.21253446.
- 396 13. Kuitunen I, Renko M. Lessons to learn from the current pandemic for future  
397 non-pharmaceutical interventions against the respiratory syncytial virus –  
398 nationwide register-study in Finland. *Infectious Diseases*. 2021:1-3.
- 399 14. Coma E, Vila J, Méndez-Boo L, et al. Reduction of respiratory syncytial virus  
400 burden of disease observed in primary care diagnosis of children under 5 years  
401 old during the COVID-19 pandemic: a time-series analysis using routinely  
402 collected data from primary care electronic health records in Catalonia  
403 (Spain). *medRxiv*. 2021:2021.2001.2027.21250063.

- 404 15. Yeoh DK, Foley DA, Minney-Smith CA, et al. The impact of COVID-19  
405 public health measures on detections of influenza and respiratory syncytial  
406 virus in children during the 2020 Australian winter. *Clinical infectious  
407 diseases: an official publication of the Infectious Diseases Society of America.*  
408 2020.
- 409 16. National Institute for Communicable Diseases SA. *INCREASE IN  
410 RESPIRATORY SYNCYTIAL VIRUS (RSV) CASES 2020.*
- 411 17. Ferrero F, Ossorio MF. Is there a place for bronchiolitis in the COVID-19 era?  
412 Lack of hospitalizations due to common respiratory viruses during the 2020  
413 winter. *Pediatric pulmonology*.n/a(n/a).
- 414 18. Respiratory virus detections in Canada. Government of Canada. 2021;  
415 [www.canada.ca/en/public-health/services/surveillance/respiratory-virus-  
416 detections-canada.html](http://www.canada.ca/en/public-health/services/surveillance/respiratory-virus-detections-canada.html). Accessed April 16, 2021.
- 417 19. Healthcare Cost and Utilization Project State Inpatient Databases. Agency for  
418 Healthcare Research and Quality. 2014; [http://www.hcup-  
419 us.ahrq.gov/sidoverview.jsp](http://www.hcup-us.ahrq.gov/sidoverview.jsp). Accessed December 2, 2020.
- 420 20. Pisesky A, Benchimol EI, Wong CA, et al. Incidence of Hospitalization for  
421 Respiratory Syncytial Virus Infection amongst Children in Ontario, Canada: A  
422 Population-Based Study Using Validated Health Administrative Data. *PloS  
423 one*. 2016;11(3):e0150416.
- 424 21. American Community Survey 1-Year Data (2005-2019). United States Census  
425 Bureau. [https://www.census.gov/data/developers/data-sets/acs-  
426 1year.2010.html](https://www.census.gov/data/developers/data-sets/acs-1year.2010.html). Accessed April 1, 2021.
- 427 22. Natality Information, Centers for Disease Control and Prevention. 1995-2019;  
428 <https://wonder.cdc.gov/natality.html>. Accessed April 5, 2020.

- 429 23. Clinical Sentinel Laboratory Influenza and Other Respiratory Virus  
430 Surveillance Data. Immunization Branch, California Department of Public  
431 Health. 2009-2018; <https://data.chhs.ca.gov/dataset/influenza-surveillance>.  
432 Accessed May 20, 2021.
- 433 24. Pitzer VE, Viboud C, Alonso WJ, et al. Environmental Drivers of the  
434 Spatiotemporal Dynamics of Respiratory Syncytial Virus in the United States.  
435 *PLOS Pathogens*. 2015;11(1):e1004591.
- 436 25. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The  
437 impact of COVID-19 nonpharmaceutical interventions on the future dynamics  
438 of endemic infections. *Proc Natl Acad Sci U S A*. 2020;117(48):30547-30553.
- 439 26. Team IC-F. Modeling COVID-19 scenarios for the United States. *Nat Med*.  
440 2021;27(1):94-105.
- 441 27. See Reopening Plans and Mask Mandates for All 50 States. The New York  
442 Times. [https://www.nytimes.com/interactive/2020/us/states-reopen-map-](https://www.nytimes.com/interactive/2020/us/states-reopen-map-coronavirus.html)  
443 [coronavirus.html](https://www.nytimes.com/interactive/2020/us/states-reopen-map-coronavirus.html). Accessed April 15, 2021.
- 444 28. Hallas L, Hatibie A, Majumdar S, Pyarali M, Hale T. Variation in US states'  
445 responses to COVID-19\_2.0.  
446 [https://www.bsg.ox.ac.uk/research/publications/variation-us-states-responses-](https://www.bsg.ox.ac.uk/research/publications/variation-us-states-responses-covid-19)  
447 [covid-19](https://www.bsg.ox.ac.uk/research/publications/variation-us-states-responses-covid-19). Accessed May 20, 2021.
- 448 29. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to  
449 estimate age-specific transmission parameters for respiratory-spread infectious  
450 agents. *American journal of epidemiology*. 2006;164(10):936-944.
- 451 30. van Hoek AJ, Andrews N, Campbell H, Amirthalingam G, Edmunds WJ,  
452 Miller E. The social life of infants in the context of infectious disease

- 453 transmission; social contacts and mixing patterns of the very young. *PloS one*.  
454 2013;8(10):e76180.
- 455 31. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries  
456 using contact surveys and demographic data. *PLoS Comput Biol*.  
457 2017;13(9):e1005697.
- 458 32. Feehan DM, Mahmud AS. Quantifying population contact patterns in the  
459 United States during the COVID-19 pandemic. *Nat Commun*. 2021;12(1):893.
- 460 33. Yan Y, Malik AA, Bayham J, Fenichel EP, Couzens C, Omer SB. Measuring  
461 voluntary and policy-induced social distancing behavior during the COVID-19  
462 pandemic. *Proc Natl Acad Sci U S A*. 2021;118(16).
- 463 34. Air Travel - Total - Seasonally Adjusted. U.S. Department of Transportation.  
464 Bureau of Transportation Statistics. February 2021;  
465 [https://data.bts.gov/Research-and-Statistics/Air-Travel-Total-Seasonally-](https://data.bts.gov/Research-and-Statistics/Air-Travel-Total-Seasonally-Adjusted/gmwv-css9)  
466 [Adjusted/gmwv-css9](https://data.bts.gov/Research-and-Statistics/Air-Travel-Total-Seasonally-Adjusted/gmwv-css9). Accessed May 5, 2021.
- 467 35. Lasry A, Kidder D, Hast M, et al. Timing of Community Mitigation and  
468 Changes in Reported COVID-19 and Community Mobility - Four U.S.  
469 Metropolitan Areas, February 26-April 1, 2020. *MMWR Morb Mortal Wkly*  
470 *Rep*. 2020;69(15):451-457.
- 471 36. Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what  
472 decides the outcome? *Nat Rev Immunol*. 2010;10(7):514-526.
- 473 37. Foley DA, Yeoh DK, Minney-Smith CA, et al. The Interseasonal Resurgence  
474 of Respiratory Syncytial Virus in Australian Children Following the  
475 Reduction of Coronavirus Disease 2019-Related Public Health Measures.  
476 *Clinical infectious diseases : an official publication of the Infectious Diseases*  
477 *Society of America*. 2021.

- 478 38. Detsky AS, Bogoch, II. COVID-19 in Canada: Experience and Response.  
479 *JAMA*. 2020;324(8):743-744.
- 480 39. Rabinovich GA, Geffner J. Facing up to the COVID-19 pandemic in  
481 Argentina. *Nat Immunol*. 2021;22(3):264-265.
- 482 40. Individual and community-based measures to mitigate the spread of COVID-  
483 19 in Canada. Government of Canada. 2021; [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/public-health-measures-mitigate-covid-19.html)  
484 [health/services/diseases/2019-novel-coronavirus-infection/health-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/public-health-measures-mitigate-covid-19.html)  
485 [professionals/public-health-measures-mitigate-covid-19.html](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/public-health-measures-mitigate-covid-19.html). Accessed April  
486 16, 2021.
- 487 41. Chambers B. Argentina's president announces new COVID restrictions.  
488 ANADOLU AGENCY. April 15, 2021;  
489 [https://www.aa.com.tr/en/americas/argentina-s-president-announces-new-](https://www.aa.com.tr/en/americas/argentina-s-president-announces-new-covid-restrictions/2209392)  
490 [covid-restrictions/2209392](https://www.aa.com.tr/en/americas/argentina-s-president-announces-new-covid-restrictions/2209392). Accessed May 15, 2021.
- 491 42. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory  
492 Syncytial Virus Seasonality: A Global Overview. *The Journal of infectious*  
493 *diseases*. 2018;217(9):1356-1364.
- 494 43. Pelletier JH, Au AK, Fuhrman D, Clark RSB, Horvat C. Trends in  
495 Bronchiolitis ICU Admissions and Ventilation Practices: 2010-2019.  
496 *Pediatrics*. 2021.
- 497 44. Alverson B, Ralston S. ICU Use in Bronchiolitis: Why Has It Doubled?  
498 *Pediatrics*. 2021:e2020046276.
- 499 45. Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE.  
500 Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-  
501 Optimal Protection Against Respiratory Syncytial Virus. *Clinical infectious*

- 502 *diseases : an official publication of the Infectious Diseases Society of America.*  
503 2015;61(4):506-514.
- 504 46. Peret TC, Hall CB, Hammond GW, et al. Circulation patterns of group A and  
505 B human respiratory syncytial virus genotypes in 5 communities in North  
506 America. *The Journal of infectious diseases.* 2000;181(6):1891-1896.
- 507 47. Anderson LJ, Hendry RM, Pierik LT, Tsou C, McIntosh K. Multicenter study  
508 of strains of respiratory syncytial virus. *The Journal of infectious diseases.*  
509 1991;163(4):687-692.
- 510 48. Agoti CN, Otieno JR, Ngama M, et al. Successive Respiratory Syncytial Virus  
511 Epidemics in Local Populations Arise from Multiple Variant Introductions,  
512 Providing Insights into Virus Persistence. *J Virol.* 2015;89(22):11630-11642.
- 513 49. Pitzer VE, Lipsitch M. Exploring the relationship between incidence and the  
514 average age of infection during seasonal epidemics. *J Theor Biol.*  
515 2009;260(2):175-185.
- 516 50. Madhi SA, Polack FP, Piedra PA, et al. Respiratory Syncytial Virus  
517 Vaccination during Pregnancy and Effects in Infants. *The New England*  
518 *journal of medicine.* 2020;383(5):426-439.
- 519 51. Influenza and Other Respiratory Viruses Weekly Report. California  
520 Department of Public Health. May 9, 2021;  
521 [https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Lib](https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/Week2020-2119_FINALReport.pdf)  
522 [rary/Immunization/Week2020-2119\\_FINALReport.pdf](https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/Week2020-2119_FINALReport.pdf). Accessed May 24,  
523 2021.
- 524 52. RSV surveillance activity summary. Florida Department of Health. May 16,  
525 2021; [http://www.floridahealth.gov/diseases-and-conditions/respiratory-](http://www.floridahealth.gov/diseases-and-conditions/respiratory-syncytial-virus)  
526 [syncytial-virus](http://www.floridahealth.gov/diseases-and-conditions/respiratory-syncytial-virus).

- 527 53. Weekly influenza & respiratory activity: Statistics. Minnesota Department of  
528 Health. May 22, 2021;  
529 <https://www.health.state.mn.us/diseases/flu/stats/index.html>. Accessed May  
530 30, 2021.
- 531 54. Oregon and Southwest Washington RSV Surveillance. Oregon Health  
532 Authority. May 26, 2021;  
533 [https://www.oregon.gov/oha/ph/DISEASES/CONDITIONS/COMMUNICABLE/DISEASE/SURVEILLANCE/RSV/SurveillanceData/Pages/RespiratorySyncytial](https://www.oregon.gov/oha/ph/DISEASES/CONDITIONS/COMMUNICABLE/DISEASE/SURVEILLANCE/RSV/SurveillanceData/Pages/RespiratorySyncytialVirusSurveillanceData.aspx)  
534 [VirusSurveillanceData.aspx](https://www.oregon.gov/oha/ph/DISEASES/CONDITIONS/COMMUNICABLE/DISEASE/SURVEILLANCE/RSV/SurveillanceData/Pages/RespiratorySyncytialVirusSurveillanceData.aspx). Accessed May 30, 2021.
- 536 55. RSV Data by health service region. Texas Health and Human Services. May  
537 25, 2021; <https://www.dshs.texas.gov/IDCU/disease/rsv/Data/>. Accessed May  
538 30, 2021.
- 539 56. PATH. RSV Vaccine and mAb Snapshot. April 2021;  
540 <https://path.org/resources/rsv-vaccine-and-mab-snapshot/>. Accessed May 28,  
541 2021.
- 542 57. AstraZeneca. Nirsevimab MELODY Phase III trial met primary endpoint of  
543 reducing RSV lower respiratory tract infections in healthy infants. Accessed  
544 26 April 2021.
- 545 58. Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of  
546 RSV in Preterm Infants. *The New England journal of medicine*.  
547 2020;383(5):415-425.  
548

549 **Figure legends**

550 **Figure 1. Expected RSV hospitalizations under different scenarios, New York,**

551 **2019–2025.** A) The impacts of mitigation measures on RSV epidemics. The dotted

552 dark pink line shows the counterfactual scenario that there is no COVID-19 pandemic

553 and no mitigation measures in place. The solid lines show three scenarios of

554 stringency of mitigation measures. The green line represents Scenario 1: 20% constant

555 decrease in transmission from March 2020 to March 2021. The orange line represents

556 Scenario 2: a sudden 20% decrease in RSV transmission in March 2020 followed by a

557 linear increase back to normal. The purple line represents Scenario 3: 82% decreased

558 non-household contacts and 10% increased household contacts between April and

559 July 2020. The red rectangle on the top, the gradient red rectangle in the middle and

560 the blue rectangle on the bottom indicate the length and the stringency of Scenarios 1-

561 3, respectively. B) The impacts of importation of external infections on Scenario 2.

562 The solid orange line is the same as the orange line in panel A), corresponding to

563 Scenario 2. The dashed lines represent a range of background importations of external

564 infections. The grey shaded area indicates a 100% to 60% decrease in external

565 infections because of the reduced air traffic between March 2020 to March 2021.

566 **Figure 2. The average age of RSV hospitalization among children under 5.** The

567 background color represents the incidence of RSV hospitalization in each age group

568 in each month. Darker red colors indicate a higher incidence. The black line and

569 values indicate the average age of hospitalization varies with time.

570 **Figure 3. Age distribution of RSV infections, LRIs and hospitalizations, 2021-**

571 **2022 RSV season.** Panels A to C correspond to RSV infections, RSV LRIs and RSV

572 hospitalizations, respectively. The red bars show the counterfactual incidence of RSV

573 cases during the 2021-2022 RSV season if there was no COVID-19 pandemic and no



574 mitigation measures in place. The blue bars show the expected incidence of RSV  
575 cases under Scenario 2 during the 2021-2022 RSV season. The numbers on the top  
576 show the percentage difference between the expected incidence and the counterfactual  
577 incidence in each age group.  
578

579 **Tables**

580 **Box 1 Description of the Five Simulations**

---

**Scenarios**

---

**Stringency of mitigation measures**

- |   |  |
|---|--|
| 1. Constant decrease in transmission                  | Individuals obey social distancing strictly and have constant low contact rate from March 2020 to March 2021   |
| 2. Sudden decrease + gradual increase in transmission | Mitigation measures are most strict at the beginning and are gradually relaxed between March 2020 and March 2021   |
| 3. Decrease in non-household contacts                 | Stay-at-home orders from late March 2020 to late June 2020 reduced contact opportunities in non-household settings by 82% and increased household contacts by 10%. |

**Factors impacting the reemergence of RSV epidemics**

- |   |   |
|---|---|
| 4. Importation of external infections                       | Introduction of the virus from other regions may ignite RSV epidemics   |
| 5. Decrease in the duration of protective maternal immunity | Absence of RSV epidemics leads to lack of boosting of maternal immunity |

---

581





